Literature DB >> 20537601

Tracing the tumor lineage.

Nicholas E Navin1, James Hicks.   

Abstract

Defining the pathways through which tumors progress is critical to our understanding and treatment of cancer. We do not routinely sample patients at multiple time points during the progression of their disease, and thus our research is limited to inferring progression a posteriori from the examination of a single tumor sample. Despite this limitation, inferring progression is possible because the tumor genome contains a natural history of the mutations that occur during the formation of the tumor mass. There are two approaches to reconstructing a lineage of progression: (1) inter-tumor comparisons, and (2) intra-tumor comparisons. The inter-tumor approach consists of taking single samples from large collections of tumors and comparing the complexity of the genomes to identify early and late mutations. The intra-tumor approach involves taking multiple samples from individual heterogeneous tumors to compare divergent clones and reconstruct a phylogenetic lineage. Here we discuss how these approaches can be used to interpret the current models for tumor progression. We also compare data from primary and metastatic copy number profiles to shed light on the final steps of breast cancer progression. Finally, we discuss how recent technical advances in single cell genomics will herald a new era in understanding the fundamental basis of tumor heterogeneity and progression. (c) 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20537601      PMCID: PMC2904844          DOI: 10.1016/j.molonc.2010.04.010

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  107 in total

Review 1.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  Rudolf Carl Virchow: medical scientist, social reformer, role model.

Authors:  Theodore M Brown; Elizabeth Fee
Journal:  Am J Public Health       Date:  2006-10-31       Impact factor: 9.308

3.  Aneuploidy of chromosome 8 as detected by interphase fluorescence in situ hybridization is a recurrent finding in primary and metastatic breast cancer.

Authors:  S Roka; M Fiegl; N Zojer; M Filipits; R Schuster; B Steiner; R Jakesz; H Huber; J Drach
Journal:  Breast Cancer Res Treat       Date:  1998-03       Impact factor: 4.872

Review 4.  Errors in DNA replication as a basis of malignant changes.

Authors:  L A Loeb; C F Springgate; N Battula
Journal:  Cancer Res       Date:  1974-09       Impact factor: 12.701

5.  Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells.

Authors:  C A Klein; O Schmidt-Kittler; J A Schardt; K Pantel; M R Speicher; G Riethmüller
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

6.  Genome-wide allelic state analysis on flow-sorted tumor fractions provides an accurate measure of chromosomal aberrations.

Authors:  Willem E Corver; Anneke Middeldorp; Natalja T ter Haar; Ekaterina S Jordanova; Marjo van Puijenbroek; Ronald van Eijk; Cees J Cornelisse; Gert Jan Fleuren; Hans Morreau; Jan Oosting; Tom van Wezel
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 7.  Breast tumor heterogeneity: cancer stem cells or clonal evolution?

Authors:  Lauren L Campbell; Kornelia Polyak
Journal:  Cell Cycle       Date:  2007-08-17       Impact factor: 4.534

Review 8.  Breast cancer: origins and evolution.

Authors:  Kornelia Polyak
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

9.  Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups.

Authors:  N Pandis; Y Jin; L Gorunova; C Petersson; G Bardi; I Idvall; B Johansson; C Ingvar; N Mandahl; F Mitelman
Journal:  Genes Chromosomes Cancer       Date:  1995-03       Impact factor: 5.006

10.  Efficient tumour formation by single human melanoma cells.

Authors:  Elsa Quintana; Mark Shackleton; Michael S Sabel; Douglas R Fullen; Timothy M Johnson; Sean J Morrison
Journal:  Nature       Date:  2008-12-04       Impact factor: 49.962

View more
  61 in total

1.  On the molecular biology of breast cancer.

Authors:  Anne-Lise Børresen-Dale; Therese Sørlie; Vessela N Kristensen
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  Accurate reconstruction of the temporal order of mutations in neoplastic progression.

Authors:  Kathleen Sprouffske; John W Pepper; Carlo C Maley
Journal:  Cancer Prev Res (Phila)       Date:  2011-04-13

Review 3.  Advances and applications of single-cell sequencing technologies.

Authors:  Yong Wang; Nicholas E Navin
Journal:  Mol Cell       Date:  2015-05-21       Impact factor: 17.970

4.  Clonal evolution and genome stability in a 2500-year-old fungal individual.

Authors:  James B Anderson; Johann N Bruhn; Dahlia Kasimer; Hao Wang; Nicolas Rodrigue; Myron L Smith
Journal:  Proc Biol Sci       Date:  2018-12-19       Impact factor: 5.349

Review 5.  Organelles - understanding noise and heterogeneity in cell biology at an intermediate scale.

Authors:  Amy Y Chang; Wallace F Marshall
Journal:  J Cell Sci       Date:  2017-02-09       Impact factor: 5.285

Review 6.  Understanding tumor heterogeneity as functional compartments--superorganisms revisited.

Authors:  Thomas G P Grunewald; Saskia M Herbst; Jürgen Heinze; Stefan Burdach
Journal:  J Transl Med       Date:  2011-05-27       Impact factor: 5.531

Review 7.  Evolution of the cancer genome.

Authors:  Ondrej Podlaha; Markus Riester; Subhajyoti De; Franziska Michor
Journal:  Trends Genet       Date:  2012-02-16       Impact factor: 11.639

Review 8.  Modeling Tumor Clonal Evolution for Drug Combinations Design.

Authors:  Boyang Zhao; Michael T Hemann; Douglas A Lauffenburger
Journal:  Trends Cancer       Date:  2016-03

9.  A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses.

Authors:  R R Naik; A K Singh; A M Mali; M F Khirade; S A Bapat
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

Review 10.  Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.

Authors:  José I López; Javier C Angulo
Journal:  Curr Urol Rep       Date:  2018-01-27       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.